Matthew Osborne
Public Communications Contact chez Apple Tree venture Managemnet Llc//vc
Profil
Matthew is head of ATP portfolio company investor relations.
He brings to this role more than 20 years of biotechnology investor relations, corporate strategic finance, and equity research analyst experience.
He has served as chief financial officer of Senda Biosciences, OncXerna Therapeutics, and Unum Therapeutics (now Cogent), where at each of these companies he formulated and implemented financial planning and fundraising efforts as well as scientific and corporate communications and investor relations activities.
He has also served as vice president of corporate affairs, communications and investor relations at Voyager Therapeutics, vice president of investor relations and communications at Synageva BioPharma (acquired by Alexion), head of investor relations at Shire Plc (acquired by Takeda) and director of investor relations at Vertex.
As a biotechnology sell-side equity analyst at Lazard Capital Markets, Matthew launched several biotech IPOs and analyzed the development of several blockbuster drugs across many therapeutic areas and modalities, having served as an associate analyst previously at Leerink Swann (now Leerink Partners).
Matthew earned his BS in Biology from Syracuse University and an MBA from the D’Amore-McKim School of Business at Northeastern University.
Postes actifs de Matthew Osborne
| Sociétés | Poste | Début |
|---|---|---|
Apple Tree venture Managemnet Llc//vc
 Apple Tree venture Managemnet Llc//vc Investment ManagersFinance Apple Tree venture Managemnet LLC (Apple Tree Partners) is a venture capital firm founded by Seth Harrison in 1999. The firm is headquartered in New York with an additional offices in London, San Francisco and Cambridge. | Public Communications Contact | 01/09/2022 |
Anciens postes connus de Matthew Osborne
| Sociétés | Poste | Fin |
|---|---|---|
Senda Biosciences, Inc.
 Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Directeur Financier/CFO | 01/10/2022 |
Oncxerna Therapeutics, Inc.
 Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | Directeur Financier/CFO | 01/06/2021 |
| COGENT BIOSCIENCES, INC. | Directeur Financier/CFO | 01/06/2020 |
| COGENT BIOSCIENCES, INC. | Directeur Financier/CFO | 29/05/2020 |
| VOYAGER THERAPEUTICS, INC. | Investor Relations Contact | 01/01/2019 |
Formation de Matthew Osborne
| Syracuse University | Undergraduate Degree |
| D'Amore-Mckim School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| VOYAGER THERAPEUTICS, INC. | Health Technology |
| COGENT BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 9 |
|---|---|
C. E. Unterberg, Towbin, Inc.
 C. E. Unterberg, Towbin, Inc. Investment Banks/BrokersFinance C. E. Unterberg, Towbin is a global investment bank headquartered in New York City with additional offices in California and Israel. The firm provides investment banking, research and investment management services to emerging growth companies and investors in the technology, health care and defense, security and diversified technology sectors. C. E. Unterberg was founded in 1932 by Clarence Unterberg. In 1977, the firm merged with L. F. Rothschild to form L. F. Rothschild, Unterberg, Towbin. In 1990, the firm again became privately owned and independent when Clarence Unterberg's son, Thomas I. Unterberg, re-launched the firm as a full-service investment bank. | Finance |
Leerink Partners LLC
 Leerink Partners LLC Investment Banks/BrokersFinance Leerink Partners LLC is a full-service brokerage and investment banking firm headquartered in Boston, Massachusetts. The firm was founded by Jeffrey Leerink in 1995 and formerly known as SVB Securities LLC. They rebranded as Leerink Partners in 2023. The firm is a subsidiary of SVB Securities LLC. Leerink Partners provides institutional sales, equity research, institutional trading, and corporate finance and asset management services to the healthcare and technology industries. They offer superior execution capabilities in common stock, convertibles and derivatives with a singular focus on healthcare and a knowledge-led approach. | Finance |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
FM Partners Holdings LLC
 FM Partners Holdings LLC Investment Banks/BrokersFinance FM Partners Holdings LLC is a broker/dealer headquartered in New York City. The firm was formerly known as Lazard Capital Markets LLC.. They are a subsidiary of LFCM Holdings LLC. | Finance |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | Health Technology |
Apple Tree venture Managemnet Llc//vc
Apple Tree venture Managemnet Llc//vc Investment ManagersFinance Apple Tree venture Managemnet LLC (Apple Tree Partners) is a venture capital firm founded by Seth Harrison in 1999. The firm is headquartered in New York with an additional offices in London, San Francisco and Cambridge. | Finance |
Senda Biosciences, Inc.
Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
